

Navana Pharmaceuticals Limited


Interim Financial Statements (Un-audited)
For the Period from 01 July 2022 -31 December 2022

Navana Pharmaceuticals Limited
Statement of Financial Position (Un-audited)
As at 31 December 2022

(Amount in BDT)

Particulars	Notes	As at	
		31-Dec-2022	30-Jun-2022
Assets			
Non-Current Assets:			
Property, Plant and Equipment	3.00	3,708,051,685	3,421,837,366
Intangible Asset	3.01	660,000	770,000
Capital Work in Progress	4.00	199,027,819	403,007,534
Right-of-Use Asset	5.00	187,384,430	204,018,990
Investment in Marketable Securities (Fair Value)	6.00	169,427,247	159,028,097
Total Non-Current Assets		4,264,551,181	4,188,661,986
Current Assets:			
Inventories	7.00	1,134,199,016	1,009,145,823
Trade and Other Receivables	8.00	589,172,658	547,819,881
Advances, Deposits and Prepayments	9.00	1,851,955,753	1,204,469,458
Goods In Transit	10.00	261,902,280	67,575,600
Cash and Cash Equivalents	11.00	650,489,616	66,427,585
Total Current Assets		4,487,719,322	2,895,438,346
Total Assets		8,752,270,503	7,084,100,333
Equity And Liabilities			
Equity:			
Paid-up Share Capital	12.00	1,074,162,170	802,301,500
Share Premium	13.00	450,209,562	-
Revaluation Reserve	14.00	1,966,271,633	1,966,271,633
Capital Reserve		605,590,148	605,590,148
Unrealized Gain/ (Loss) Reserve	6.00	(76,189,889)	(95,356,927)
Retained Earnings		229,642,054	204,242,971
Total Equity:		4,249,685,678	3,483,049,324
Liabilities			
Non-Current Liabilities:			
Loan from Directors	15.00	30,000,000	30,000,000
Lease Liabilities	16.02	104,350,155	100,720,006
Long Term Loan	17.02	25,820,495	141,390,720
Deferred Tax Liability	18.00	46,927,303	42,362,502
Total Non-Current Liabilities		207,097,953	314,473,228
Current Liabilities:			
Short Term Loan	19.00	3,602,714,114	2,682,055,890
Lease Liabilities (Current Maturity)	16.01	24,691,658	29,254,646
Long Term Loan (Current Maturity)	17.01	5,845,498	28,125,222
Trade and Other Payables	20.00	544,077,764	547,142,023
Dividend Payable		118,157,839	-
Total Current Liabilities		4,295,486,872	3,286,577,781
Total Liabilities		4,502,584,825	3,601,051,009
Total Equity and Liabilities		8,752,270,503	7,084,100,333
Net Asset Value (NAV) Per Share	30.00	39.56	43.41

Annexed notes are integral part of these financial statement.


Chief Financial Officer


Company Secretary


Managing Director


Director


Director

Navana Pharmaceuticals Limited
Statement of Profit or Loss and Other Comprehensive Income (Un-audited)
For the period from 01 July 2022 to 31 December 2022

(Amount in BDT)

Particulars	Notes	Half Yearly		Second Quarter	
		July-Dec'2022	July-Dec'2021	Oct-Dec'2022	Oct-Dec'2021
Net Sales	21.00	2,731,985,726	2,437,458,065	1,395,860,103	1,232,261,592
Less: Cost of Good Sold	22.00	1,475,493,092	1,356,630,333	747,501,671	694,774,789
Gross Profit		1,256,492,634	1,080,827,732	648,358,431	537,486,803
Less: Operating Expenses					
Administrative Expenses	23.00	100,786,936	82,384,963	59,288,682	44,692,136
Selling & Marketing Expenses	24.00	616,649,993	614,865,227	332,820,480	328,509,489
Distribution Expenses	25.00	188,586,128	148,947,190	95,129,309	72,697,585
Total Operating Expenses:		906,023,057	846,197,380	487,238,471	445,899,210
Operating Profit		350,469,578	234,630,352	161,119,961	91,587,593
Less: Finance Expenses	26.00	142,607,229	95,052,933	77,309,339	42,273,407
Add: Other Income/(loss)	27.00	(15,041,693)	70,129,296	(3,675,944)	59,675,686
Profit before WPPF & Tax		192,820,655	209,706,715	80,134,678	108,989,872
Contribution to WPPF		9,181,936	9,808,223	3,815,937	5,012,182
Profit before tax		183,638,719	199,898,492	76,318,741	103,977,690
Less: Income Tax		40,081,797	76,062,807	5,392,244	41,516,859
Current Tax	28.00	35,516,996	76,311,579	18,993,226	45,951,686
Deferred Tax Expense/(Income)		4,564,800	(248,773)	(13,600,983)	(4,434,828)
Profit after Tax		143,556,922	123,835,685	70,926,497	62,460,831
Other Comprehensive Income					
Unrealized Gain/(loss) on Marketable Security		19,167,038	17,238,872	7,460,356	17,238,872
Total Comprehensive Income		162,723,960	141,074,557	78,386,853	79,699,703
Earnings Per Share (EPS)	29.00	1.57	1.54	0.77	0.78

Annexed notes are integral part of these financial statement.


Chief Financial Officer


Company Secretary


Managing Director


Director


Director


Navana Pharmaceuticals Limited
Statement of Changes in Equity (Un-audited)
For the period from 01 July 2022 to 31 December 2022

Particulars	(Amount in BDT)							
	Share Capital	Share Premium	Liability against Share Money	Revaluation Reserve	Capital Reserve	Unrealized Gain/(Loss) Reserve	Retained Earnings	Total
Balance as at 1 July 2022	802,301,500	-	-	1,966,271,633	605,590,148	(95,356,927)	204,242,971	3,483,049,324
Profit after Tax	-	-	-	-	-	-	143,556,922	143,556,922
Received from IPO Share Subscription	-	-	750,000,018	-	-	-	-	750,000,018
Allotment of Shares for IPO	271,860,670	478,139,348	(750,000,018)	-	-	-	-	(118,157,839)
11% Cash Dividend for YE 30 June 2022	-	-	-	-	-	-	(118,157,839)	(118,157,839)
Less: Adj with IPO Expense	-	(27,929,786)	-	-	-	19,167,038	-	(27,929,786)
Adj. to Unrealized Gain/(Loss) on FVOCI	-	-	-	-	-	(76,189,889)	-	19,167,038
Balance as at 31 December 2022	1,074,162,170	450,209,562	-	1,966,271,633	605,590,148	(76,189,889)	229,642,054	4,249,685,678

Particulars	(Amount in BDT)							
	Share Capital	Share Premium	Liability against Share Money	Revaluation Reserve	Capital Reserve	Unrealized Gain/(Loss) Reserve	Retained Earnings	Total
Balance as at 1 July 2021	802,301,500	-	-	1,966,271,633	-	-	535,831,580	3,304,404,713
Profit after Tax during the period	-	-	-	-	-	-	274,001,539	274,001,539
Transfer to Capital Reserve	-	-	-	-	605,590,148	-	(605,590,148)	-
Unrealized Gain/(Loss) on Marketable Securities	-	-	-	-	-	(95,356,927)	-	(95,356,927)
Balance as at 31 December 2021	802,301,500	-	-	1,966,271,633	605,590,148	(95,356,927)	204,242,971	3,483,049,324


Chief Financial Officer


Company Secretary


Managing Director


Director


Director

Navana Pharmaceuticals Limited
Statement of Cash Flows (Un-audited)
For the period from 01 July 2022 to 31 December 2022

(Amount in BDT)

Particulars	Notes	Half Yearly	
		July-Dec'2022	July-Dec'2021
Cash Flows from Operating Activities:			
Cash Received from Customers		2,675,574,518	2,355,297,392
Cash Received from Other Income		35,607,023	3,358,433
Cash Paid to Operational & Others		(2,631,526,234)	(2,311,379,331)
Net cash flows from operating Activities:		79,655,306	47,276,493
Cash Flows from Investing Activities:			
Cash Paid for Purchase of Property, Plant & Equipment		(846,628,977)	(701,072,623)
Realized Gain/(loss) from Sale of Marketable Securities		(21,762,449)	66,770,864
Cash received from Dividend Income		671,590	-
Cash Received/(Paid) from Investment in Marketable Securities		8,767,888	(331,934,982)
Net cash from/(used in) investing activities:		(858,951,949)	(966,236,741)
Cash Flows from Financing Activities:			
Cash Received from IPO Proceed		750,000,018	-
Payment for IPO Expenses		(16,036,004)	(8,655,000)
Bank & Lease Interest Paid		(153,814,509)	(95,052,933)
Receipts against Short Term Borrowings		920,658,223	1,141,690,562
Receipts against Long Term Borrowings		(137,849,949)	36,410,301
Payment against Lease Liability		(932,839)	-
Net cash from/(used in) financing activities		1,362,024,941	1,074,392,930
Change in Cash and Cash Equivalent		582,728,299	155,432,681
Cash and Cash Equivalent at the beginning of the period		66,427,585	25,776,315
Effect of exchange rate changes on Cash and Cash Equivalents		1,333,733	26,182
Cash and Cash Equivalent at the end of the period		650,489,616	181,235,178
Net Operating Cash Flow per Share (NOCFPS)		31.00	0.87
			0.59


Chief Financial Officer


Company Secretary


Managing Director


Director


Director